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ABSTRACT
The Epstein–Barr Virus (EBV) protein EB2 (also
called Mta, SM and BMLF1), is an essential nu-
clear protein produced during the replicative
cycle of EBV. EB2 is required for the efficient cyto-
plasmic accumulation of viral mRNAs derived from
intronless genes. EB2 is an RNA-binding protein
whose expression has been shown to influence
RNA stability, splicing, nuclear export and transla-
tion. Using a yeast two-hybrid screen, we have
identified three SR proteins, SF2/ASF, 9G8 and
SRp20, as cellular partners of EB2. Then, by using
siRNA to deplete cells of specific SR proteins, we
found that SRp20 plays an essential role in the
processing of several model mRNAs: the Renilla
luciferase reporter mRNA, the human b-globin
cDNA transcript and two EBV late mRNAs. These
four mRNAs were previously found to be highly
dependent on EB2 for their efficient cytoplas-
mic accumulation. Here, we show that SRp20
depletion results in an increase in the accumu-
lation of these mRNAs, which correlates with
an absence of additive effect of EB2, suggesting
that EB2 functions by antagonizing SRp20.
Moreover, by using RNA-immunoprecipitation
assays we found that EB2 enhances the association
of SRp20 with the b-globin transcript suggesting
that EB2 acts by stabilizing SRp20’s labile inter-
actions with the RNA.
INTRODUCTION
In eukaryotic cells, nuclear export of mRNAs is mediated
by conserved proteins which coat the nascent RNA
co-transcriptionally to form export-competent mRNPs
that are capped at their 50-end, spliced, and cleaved/
polyadenylated at their 30-end [for a review, see (1)].
Translocation of mRNPs through the nuclear pore
complex requires binding of a heterodimer composed of
NXF1 and NXT1 (respectively Mex67 and Mtr2 in
Saccharomyces cerevisiae), which escorts competent
mRNPs out of the nucleus via direct interactions
with nucleoporins lining the nuclear pore. Because of
its low afﬁnity for binding mRNAs, the heterodimer
NXF1:NXT1 requires adaptator proteins, amongst
which the best characterized is REF (2). In higher eukary-
otes the recruitment of NXF1:NXT1 to mature mRNAs
appears to be dependent upon 50-cap addition and
splicing. Two multiprotein complexes are known to
be recruited as a consequence of splicing: the exon–
junction complex (EJC) which is deposited
20–24 nt upstream of the exon–exon junction during
splicing and which is associated with nonsense-mediated
mRNA decay (NMD), and the human transcription/
export complex (hTREX). hTREX contains the
hTHO-complex (composed of hHpr1, hTho2, fSAP79,
fSAP35 and fSAP24) associated with the RNA helicase
UAP56 and the adaptator protein REF. Recent studies
strongly suggest that the cap-binding protein CBP80 and
factors deposited at the ﬁrst exon–exon junction by
splicing, cooperate to recruit hTREX onto spliced
mRNAs (3). The presence of REF in this complex is
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thought to stimulate the recruitment of NXF1 onto the
mRNPs and lead to their efﬁcient export through the
nuclear pore.
FormRNAs generated from intronless genes, two export
pathways have been described. One implicates binding of
SR proteins 9G8 and SRp20 to mRNAs (4). Similarly to
REF, these two shuttling SR proteins have been found to
serve as RNA-binding adaptors for NXF1 (5). The other
pathway implicates recruitment of REF at the 50-end of the
mRNA by the cap-binding protein CBP20 (6).
In contrast to the majority of mammalian genes, most
herpesvirus early and late genes are intronless. The efﬁ-
cient cytoplasmic accumulation of most of these intronless
viral mRNAs appears to be strictly dependent on a viral
gene product that shares properties with known mRNA
export adaptors. The most studied of these factors are the
herpes simplex virus type 1 (HSV1) protein ICP27 (7,8),
the cytomegalovirus (CMV) protein UL69 (9), the
Kaposi’s sarcoma-associated herpes virus (KSHV)
protein ORF57 (10,11), the herpes virus saimiri
(HVS) protein ORF57 (12), the Varicella-Zoster virus
(VZV) protein IE4 (13) and the Epstein–Barr virus
(EBV) protein EB2 (also known as BMLF1, SM and
Mta) (14,15). The EB2 protein of EBV is absolutely
required for production of infectious viral particles (16).
It binds RNA in vitro and in vivo via an arginine-rich
region (17) and induces the cytoplasmic accumulation of
most early and late viral mRNAs (16,18,19) both by inter-
acting with cellular adaptators of the NXF1/NXT1
receptor pathway such as REF (20) or OTT1/RBM15
and OTT3/RBM15b (21), two RNA-binding proteins
that belong to the human Spen (split end) protein family
(22,23), and by directly interacting with NXF1 (24). Like
cellular mRNA export factors, EB2 shuttles between the
nucleus and the cytoplasm (14,20,24) and we have recently
shown that it associates with polyribosomes and strongly
stimulates translation of its target mRNAs (25).
Moreover, it has recently been shown that EB2/SM modu-
lates splice site selection of the host-cell STAT1
pre-mRNA by directly interacting with the cellular
splicing factor SRp20 (26,27)
In order to better understand the mechanisms involved
in the multiple functions of EB2, both in viral mRNA
processing and translation, we used a wide yeast
two-hybrid screen to identify the principal interactions
of EB2 with the cellular proteome. Interestingly, we
found speciﬁc interactions with three members of the SR
protein family: SF2/ASF (SRSF1), SRp20 (SRSF3) and
9G8 (SRSF7). The SR protein family comprises a number
of phylogenetically conserved and structurally related
proteins. They have a common organization with the
presence of one or two RNA recognition motifs (RRMs)
at their N-termini that provide RNA-binding speciﬁcity,
and a domain rich in arginine and serine dipeptides,
termed the RS domain, at their C-termini. SR proteins
have speciﬁc, yet degenerate RNA-binding sites. They
were originally identiﬁed due to their activities as consti-
tutive and alternative pre-mRNA splicing factors [for a
review see (28,29)]. However, a subset of SR proteins,
which includes SF2/ASF, SRp20 and 9G8, has been
found to play additional roles in RNA processing. For
example, SF2/ASF has been implicated in mRNA trans-
lation of an ESE (exonic splicing enhancer)-containing
luciferase reporter (30,31), SRp20 has been shown to
function in IRES (internal ribosome entry site)-mediated
translation of viral RNA (32) and 9G8 in translation of
un-spliced mRNA containing a CTE (constitutive trans-
port element) (33). Moreover, SRp20 and 9G8 have been
found to function in the nucleocytoplasmic export of
mRNA by interacting with the mRNA nuclear export
factor NXF1 (4,5).
After conﬁrming the interactions found in the
two-hybrid screen between EB2 and the three SR
proteins by GST–pull-down and co-immunoprecipitation
assays, we have studied the impact of depletion of these
SR proteins from cells for the EB2-dependent cytoplasmic
accumulation of two model transcripts generated from
intronless reporter genes as well as two late viral
mRNAs and virus particle production. Our results have
led us to propose a new mechanism by which a viral
protein enhances mRNA accumulation by antagonizing
the action of SR proteins.
MATERIALS AND METHODS
Human lymphoblastoid cell cDNA library
Human peripheral blood mononuclear cells (PBMC) were
freshly isolated by density-gradient centrifugation using
Ficoll Hypaque (Sigma). B cells were puriﬁed from the
PBMCs using anti-CD19 coated nanoparticules (EasySep,
Stem Cell Technologies). Puriﬁed B cells were infected with
a recombinant EBV expressingGFP as previously described
(34) and infected cells were selected by hygromycin treat-
ment. After several weeks in culture the resulting
immortalized cells were used to generate a cDNA library
in pACT2-GW (Invitrogen) (1.33 107 primary clones).
Plasmids
ORFs for full-length EB2, EB2Nter (amino acids 1–184)
and EB2Cter (amino acids 185–479) were cloned in a
Gateway recombinational cloning system (35) and de-
posited in a viral ORF repositery, viralORFeome (36).
Each ORF was PCR-ampliﬁed (with KOD polymerase,
Novagen) using attB1 and attB2 recombination sites
fused to forward and reverse primers, then cloned into
pDONR207 (BP Clonase, Invitrogen). The ORFs were
subsequently transferred (LR Clonase, Invitrogen) into
the bait vector, pGBKT7, to be expressed as Gal4-DB
fusions in yeast. Plasmids pCI-FlagEB2, pCI-
FlagEB2Nter, pCI-FlagEB2Cter, pCI-FlagEB2 M1.2,
pCI-FlagEB2Nter M1.2, pGEX-EB2Nter and pGEX-
EB2Cter have been previously described (20,37).
pGEX-SRp20, pGEX-9G8, pGEX-SF2/ASF have also
been previously described (13). pGEX-SRp20 RRM was
constructed by insertion of a stop codon at position 104 in
pGEX-SRp20 by site-directed mutagenesis (QuickChange
Site-Directed Mutagenesis kit, Stratagene). pGEX-SRp20
RS was generated by cloning a PCR-ampliﬁed SRp20
fragment into the pDEST15 vector (Invitrogen) using
Gateway technology (Invitrogen). pDEST-MycNXF1
was generated by cloning a PCR-ampliﬁed fragment
Nucleic Acids Research, 2012, Vol. 40, No. 14 6835
into the pDEST-Myc vector (Invitrogen) using Gateway
technology (Invitrogen). Expression plasmids for HA-
SRp20, V5-SRp20, V5-9G8 and V5-SF2/ASF have been
previously described (13) as well as plasmid
pcDNAGlobinRen (25). Plasmids b1()2(), 1X-bG,
2X-bG and 4X-bG were a kind gift from Dr Y. Huang.
Plasmid pCI-FlagBFRF3-i has been previously described
(18). Plasmid pCI-FlagBDLF1-i was constructed in a
similar way to pCI-FlagBFRF3-i.
Yeast two-hybrid screens
The screens were performed by yeast mating using the
AH109 and Y187 yeast strains (Clontech) (38,39). Bait
vectors, pGBKT7-EB2, pGBKT7-EB2Nter, pGBKT7-
EB2Cter were transformed into AH109 (bait strain), and
the human lymphoblastoid cell line AD–cDNA library
was transformed into Y187 (prey strain). Single bait
strains were mated with prey strain and then diploids
were plated on SD-W-L-H+5mM 3-AT medium.
Positive clones were maintained on this selective medium
for 15 days to eliminate any contaminating AD–cDNA
plasmid (40). AD–cDNAs were ampliﬁed by colony
PCR and inserts were sequenced and identiﬁed by auto-
matic BLAST as previously described (41). All primary
positive clones were then retested in fresh yeast: bait
vectors were retransformed in the AH109 strain and
PCR-ampliﬁed prey cDNA (for each identiﬁed putative
interactor) was transformed in the Y187 strain in combin-
ation with linearized pACT2 prey vector [gap repair (42)].
All prey strains were then mated with the different bait
strains in an ‘all against all’ fashion, generating a Y2H
pairwise matrix.
Cell culture and transfections
HeLa cells and HEK293T cells were grown at 37C in
DMEM supplemented with 10% Foetal Bovine Serum
(FBS) and penicillin–streptomycin. HEK293 cells
infected with the recombinant EBV virus (HEK293EBV),
a gift from Dr W. Hammerschmidt, have been described
previously (43). The recombinant virus encodes Green
Fluorescent Protein (GFP) and the hygromycin B resist-
ance gene. HEK293EBV-BMLF1KO has been previously
described (16). HEK293EBV and HEK293EBV-BMLF1KO
cells were maintained in Dulbecco’s modiﬁed Eagle
medium (DMEM), supplemented with 10% FBS, penicil-
lin–streptomycin and hygromycin B (100mg/ml;
Invitrogen). Raji cells were maintained in RPMI 1640
medium supplemented with 10% FBS and penicillin–
streptomycin. Plasmid transfections were performed
either by the calcium phosphate precipitate method or
by using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s protocol. siRNA were transfected by
using INTERFERin (Polyplus Transfection) 48 h prior
to DNA transfections. siRNA oligonucleotide sequences
used are as follows: 50-GGAAAUAGAAGACAGUUU
G(dT)(dT)-30 and antisense for the SRp20 siRNA (32);
50-AGGAGAGUUAGAAAGGGCU(dT)(dT)-30 and
antisense for the 9G8 siRNA (44); 50-CCAAGGACAU
UGAGGACGU(dT)(dT)-30 and antisense for the SF2/
ASF siRNA (44). Fireﬂy luciferase siRNAs were used as
a control.
Virus production and titration
HEK293EBV cells or HEK293EBV-BMLF1KO cells were
transfected with pCMV-BZLF1, an expression vector
coding for the EBV transcriptional activator EB1
(also called Zta or Zebra), to activate the EBV product-
ive cycle. Supernatants from transfected cells were har-
vested at 48 h post-transfection and ﬁltered through a
0.45 -mm pore size ﬁlter. Raji cells (1 105) were incubated
in 0.5ml of virus solution for 6–8 h at 37C in a 24-well
plate. Cells were then washed, re-suspended in 1ml of
RPMI and incubated for an additional 72 h at 37C.
GFP-expressing Raji cells were quantiﬁed by FACS
analysis.
Co-immunoprecipitation assays and western blots
Transfected HEK293T cells were harvested from 100-mm
dishes 48 h post-transfection and lysed in IP buffer
(50mM Tris–HCl pH 7.5, 150mM NaCl, 1mM EDTA,
1mM DTT and 0.5% Nonidet P-40) plus protease inhibi-
tors (Roche Molecular Biochemicals) and phosphatase
inhibitors (Phosphatase Inhibitor Cocktail 2, Sigma-
Aldrich). For immunoprecipitation of the transiently ex-
pressed F.EB2 protein, cell extracts were incubated with
30 ml anti-Flag M2 afﬁnity gel (Sigma) for 4 h at 4C and
immunopuriﬁed proteins were analysed by western
blotting. Antibodies used for western blotting analysis
were an anti-Flag rabbit polyclonal antibody (Sigma), an
anti-V5 rabbit polyclonal antibody (Sigma), an
anti-SRp20 mAb (clone 7B4, Invitrogen), an anti-9G8
rabbit polyclonal antibody (Sigma), an anti-SF2/ASF
mAb (clone 96, Invitrogen) and an anti-a-Tubulin mAb
(B-5-1-2, Sigma). The appropriate anti-mouse or
anti-rabbit horseradish peroxidase (HRP)-conjugated
antibodies (GE healthcare) were used as secondary
antibodies. Myc-tagged proteins were revealed using a
c-Myc (9E10) HRP-conjugated antibody (Santa Cruz).
RNase treatment was performed by adding 2 ml of
RNase A (10mg/ml) to each reaction. Western blots
were revealed using ECL (Pierce).
In vitro GST pull-down assays
GST and GST-fusion proteins were puriﬁed from
Escherichia coli BL21 (DE3) codon plus strain extracts,
with glutathione–Sepharose 4B beads (Amersham
Biosciences). Beads carrying the GST or the GST-fusion
proteins were equilibrated in TNTB-binding buffer
(10mM Tris–HCl pH 8, 250mM NaCl, 0.1% NP40 and
2mg/ml BSA) in the presence of protease inhibitors
(complete EDTA-free cocktail from Roche Molecular
Biochemicals) and incubated with radiolabelled proteins
synthesized in vitro in the presence of [35S]-methionine
using the TnT-Coupled Transcription/Translation system
(Promega), in TNTB for 4 h at 4C. RNase treatment was
performed by adding 1 ml of RNase A (10mg/ml) and 1 ml
of RNase T1 (10U/ml) in the incubation reaction. Beads
were washed 5 in TNTB buffer without BSA and bound
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proteins were fractionated by SDS–PAGE and revealed by
autoradiography
Imunoﬂuorescence assays
For indirect immunoﬂuorescence experiments, an
anti-Flag polyclonal antibody (Sigma) and an anti-HA
mAb (Sigma) were used as primary antibodies. Alexa
Fluor 488 goat anti-rabbit antibody (Invitrogen) and a
Fluorolink Cy3-labelled goat anti-mouse IgG (H+L)
(GE Healthcare) were used as secondary antibodies. Cell
nuclei were stained by incubation with 5 mg/ml Hoescht
33258 (Sigma).
RT–PCR ampliﬁcations and RNA immunoprecipitations
RNA extractions, quantitative reverse transcription
PCR (RT–qPCR) from nuclear and cytoplasmic RNAs
were performed as previously described (25). For semi-
quantitative RT–PCR, RNA was extracted using TRIzol
(Invitrogen). Any contaminating DNA was removed from
RNA samples using RQ1 DNase (Promega). RT–PCR
was then performed using the qScript cDNA SuperMix
from Quanta (RT) and GoTaq DNA polymerase
(Promega) (PCR) in the presence of [a32P]-dCTP. The
following primer pairs were used to amplify the human
b-globin mRNA: 50-CATTTGCTTCTGACACAACTG-
30 and 50-GCAGAATCCAGATGCTCAAGG-30. b-actin,
BDLF1 and BFRF3 PCR primers have been previously
described (18,25). PCRs were performed on various
amounts of the RT reaction mixtures to obtain a lin-
early increasing signal after 25 cycles. The number of
PCR cycles used in all subsequent assays was 25. PCR
fragments were analysed on 6%polyacrylamide gels
and data were quantiﬁed by scanning the gels with a
PhosphorImager. RNA immunoprecipitations were
realized using the following protocol [modiﬁed from
Boyne et al. (45)]. HeLa cells were washed with ice-cold
PBS and UV-irradiated at 900mJ/cm2 in a Bio-Link
crosslinker (Vilbert-Lourmat). Cells were scraped,
transferred to an RNase-free tube and pelleted at
1200 rpm for 5min. Cell pellets were re-suspended
in 400ml of TAP lysis buffer (10mM HEPES, 10mM
KCl, 2mM MgCl2, 0.5% Nonidet P-40, 5% glycerol,
protease inhibitors [Roche Molecular Biochemicals),
1ml/ml RNasin (Promega)]. Cells were incubated on ice
for 30min with occasional vortexing to lyse cells. For
immunoprecipitations, protein A-Sepharose beads were
prepared, coupled either to anti-SRp20 monoclonal
antibody (Invitrogen) or anti-Flag M2 monoclonal
antibody (Sigma). The antibody-coated beads were
incubated with the cleared cell lysates for 4 h at 4C.
Beads were then washed 5 with NT2 buffer [50mM
Tris–HCl, pH 7.4, 150mM NaCl, 1mM MgCl2, 0.05%
Nonidet P-40, 1ml/ml RNasin (Promega)], and RNA was
eluted by heating at 55C for 15min in 100ml NT2 buffer
containing 0.1% SDS and 0.5mg/ml proteinase K. Beads
were pelleted, and the supernatant transferred to a fresh
RNase-free tube. RNA was then extracted and analysed
as described above.
RESULTS
Identiﬁcation of the three SR proteins, 9G8, SF2/ASF
and SRp20 as speciﬁc interactors of the EBV EB2 protein
in a yeast two-hybrid screen
We used the yeast two-hybrid (Y2H) system to identify
cellular proteins that interact with EB2. Three constructs,
encoding full length, N-terminal half (amino acids 1–184)
or C-terminal half (amino acids 185–479) of EB2 were
used to probe a human lymphoblastoid cell line
(EBV-infected) cDNA library. Three independent screens
were performed with each EB2-derived bait protein by
mating. In total, each EB2 construct was screened
against 2–8 107 human AD–Y fusion proteins and 269
clones (corresponding to 64 different putative inter-
actions) were initially characterized following PCR amp-
liﬁcation of the cDNAs and sequencing. The data set was
retested by direct Y2H between EB2 protein baits and
cellular protein preys identiﬁed by our Y2H screens
(Y2H pairwise matrices). After elimination of
autoactivators, 43 Y2H interactors were retested positive
(Table 1). From the 269 initial positive colonies, 80 cor-
responded to an interaction of EB2 with itself via its
C-terminal domain. In our list of cellular interactors,
only Sp100 (46) and RBM15B (21) have been previously
described as direct interactors for EB2. A majority of the
newly identiﬁed interactors corresponds to proteins
involved in RNA metabolism. Among them, we found
three members of the highly conserved SR protein
family, namely 9G8 (SFRS7), SF2/ASF (SFRS1) and
SRp20 (SFRS3). To conﬁrm the interaction between
EB2 and the three SR proteins in mammalian cells, we
performed co-immunoprecipitation assays. V5-tagged
9G8, SF2/ASF, SRp20—or Myc-tagged NXF1 as a
positive control—were expressed in HEK293T cells
either alone or together with Flag-tagged EB2.
Immunoprecipitations were performed using an M2
anti-Flag mAb afﬁnity gel in the presence or absence
of RNase and the immunoprecipitated complexes
were analysed by western blotting. As published previ-
ously (24), NXF1 was efﬁciently co-immunoprecipitated
with EB2 and the interaction was found to be dras-
tically reduced in the presence of RNase (Figure 1D).
Interestingly, 9G8 (panel A), SF2/ASF (panel B) and
SRp20 (panel C) were all speciﬁcally co-immunopre-
cipitated with EB2 both in the presence or absence of
RNase treatment indicating that all three SR proteins
can interact with EB2 in mammalian cells and that these
interactions are largely independent of the presence of
RNA.
EB2 interacts with 9G8, SF2/ASF and SRp20 via its
C-terminal domain
To conﬁrm that EB2 interacts directly with the SR
proteins and to identify the region of EB2 that is
involved in each interaction, we performed in vitro
binding assays by using GST fusion proteins produced
in bacteria and 35S-proteins that were in vitro-translated
in reticulocyte lysates. In a ﬁrst series of experiments,
35S-labelled EB2, EB2Nter or EB2Cter (Figure 2A) were
Nucleic Acids Research, 2012, Vol. 40, No. 14 6837
incubated with GST, GST–9G8, GST–SF2/ASF or GST–
SRp20 proteins bound to Glutathione Sepharose beads in
the presence of RNase. As shown in Figure 2B, EB2 was
efﬁciently retained on GST–9G8, GST–SF2/ASF and
GST–SRp20 but not on GST alone, which strongly
suggests a direct interaction between EB2 and each of
the three SR proteins. When we used the C-terminal half
of EB2 (EB2Cter) we observed that this protein was
retained on both GST–9G8 and GST–SRp20, but less
efﬁciently on GST–SF2/ASF. On the contrary, the
N-terminal domain of EB2 (EB2Nter) was not retained
on GST–9G8 or GST–SRp20, but a weak interaction
was detected with GST–SF2/ASF. In a reverse series
of experiments, 35S-labelled 9G8, SF2/ASF or SRp20
were incubated with GST, GST–EB2Nter or GST–
EB2Cter (Figure 2C). All three proteins were retained
on GST–EB2Cter, whereas interaction with GST–
EB2Nter was either non-detectable (SRp20) or much
Table 1. List of cellular proteins interacting with EB2 identiﬁed in the Y2H screen
NCBI GeneID Nb of hits Gene symbol Full name
RNA metabolism
6672 7 SP100 SP100 nuclear antigen
22827 9a PUF60 Poly-U-binding splicing factor 60 kDa
8175 1 SF3A2 Splicing factor 3a, subunit 2, 66 kDa
6426 3a SRSF1 Splicing factor, arginine/serine-rich 1
6432 1a SRSF7 Splicing factor, arginine/serine-rich 7, 35 kDa
6428 10a SRSF3 Splicing factor, arginine/serine-rich 3
8233 3 ZRSR2 Zinc ﬁnger (CCCH type), RNA-binding motif and serine/arginine-rich 2
3183 20a HNRNPC Heterogeneous nuclear ribonucleoprotein C (C1/C2)
29890 2a RBM15B RNA-binding motif protein 15B
Ribosome components
6138 13 RPL15 Ribosomal protein L15
6129 1 RPL7 Ribosomal protein L7
6142 6 RPL18A Ribosomal protein 18A
91582 2 RPS19BP1 Ribosomal protein S19-binding protein 1
7311 1 UBA52 Ubiquitin A-52 residue ribosomal protein fusion product 1
Transcriptional regulation
10743 3 RAI1 Retinoic acid induced 1
30836 1 DNTTIP2 Deoxynucleotidyltransferase, terminal, interacting protein2
3663 8 IRF5 Interferon regulatory factor 5
Ubiquitination
9636 3 ISG15 ISG15 ubiquitin-like modiﬁer
7329 4 UBE2I Ubiquitin-conjugating enzyme E2I (UBC9 homologue, yeast)
Others
118881 3 COMTD1 Catechol-O-methyltransferase domain containing 1
8525 3 DGKZ Diacylglycerol kinase z 104 kDa
7266 1 DNAJC7 DnaJ (Hsp40) homologue, subfamily C, member 7
4050 5 LTB Lymphotoxin b (TNF superfamily member 3)
5155 8 PDGFB sarcoma viral (v-sis oncogene homologue)
6643 2 SNX22 Sorting nexin 2
147 1 ADRA1A Adrenergic receptor, a-1B-, receptor
Unknown function
81844 2 TRIM56 Tripartite motif-containing 56
55661 24 DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27
79009 1 DDX50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50
23518 2 R3HDM1 R3H domain containing 1
51111 1 SUV420H1 Suppressor of variegation 4–20 homologue 1 (Drosophila)
65265 1 C8orf33 Chromosome 8 open reading frame 33
84273 2 C4orf14 Chromosome 4 open reading frame 14
Zinc-ﬁnger proteins
7738 1 ZNF184 Zinc-ﬁnger protein 184
63977 1 ZNF298 Zinc-ﬁnger protein 298
126295 2 ZNF57 Zinc-ﬁnger protein 57
10782 2 ZNF274 Zinc-ﬁnger protein 274
79759 1 ZNF668 Zinc-ﬁnger protein 668
163049 1 ZNF791 Zinc-ﬁnger protein 791
90987 1 ZNF251 Zinc-ﬁnger protein 251
55769 1 ZNF83 Zinc-ﬁnger protein 83
3104 1 ZBTB48 Zinc-ﬁnger and BTB domain containing 48
Viral protein
5176227 80a EB2 mRNA export factor EB2
aconﬁrmed by coIP in vivo.
Each human gene is identiﬁed by its National Center for Biotechnology Information (NCBI) gene ID (ﬁrst column), Gene symbol (third column) and
full name (fourth column). The number of independent clones found in the Y2H screen for a given partner is indicated in the second column.
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weaker (9G8 and SF2/ASF). From these experiments
we conclude that the main interaction domain between
EB2 and the three SR proteins is located in its
C-terminal half.
We then asked which domain of SRp20 was involved
in the interaction with EB2. For this, we generated
two GST–SRp20 mutant fusion proteins: one of the
fusion protein carries the N-terminal RRM (RRM)
domain, the other carries the RS-rich C-terminal domain
(Figure 3A). The results (Figure 3B) suggest that the
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Figure 1. SRp20, 9G8 and SF2/ASF coimmunoprecipitate with EB2.
V5-tagged 9G8 (A), V5-tagged SF2/ASF (B), V5-tagged SRp20 (C) or
c-Myc-tagged NXF1 (D) were expressed by transient transfection in
HEK293T cells either alone or together with Flag-tagged EB2.
Lysates were prepared and immunoprecipitations performed using an
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immunoprecipitated complexes were then analysed by western blotting
using an anti-Flag polyclonal antibody to visualize EB2, an anti-V5
polyclonal antibody to visualize 9G8, SF2/ASF and SRp20 or an
anti-c-Myc monoclonal antibody for NXF1. The ‘input’ corresponds
to 15%of the material present in the immunoprecipitated lysates.
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Figure 2. SRp20, 9G8 and SF2/ASF interacts with the C-terminal
half of EB2 in vitro. (A) Schematic representation of the EB2 protein.
The light gray box represents the nuclear export domain (NES) previ-
ously identiﬁed in the protein, the dark gray box, the RNA-binding
domain (RBD), the white box, the REF interacting domain and the
two vertical bars the Nuclear Localization Signals (NLS). Below, the
C-terminal and N-terminal deletion mutants (EB2Nter and EB2Cter
respectively) are represented. (B) 35S-labelled EB2, EB2Nter or
EB2Cter were incubated with puriﬁed GST, GST–9G8, GST–SF2/
ASF or GST–SRp20 bound to glutathione sepharose beads. The
bound proteins were analysed by SDS–PAGE and visualized by auto-
radiography. In lane 1, the equivalent of one-ﬁfth of the EB2-,
EB2Nter- or EB2Cter-expressing rabbit reticulocyte lysate used in
each assay was loaded onto the gel. (C) 35S-labelled 9G8, SF2/ASF
or SRp20 were incubated with puriﬁed GST, GST–EB2Nter or GST–
EB2Cter bound to glutathione sepharose beads. The bound proteins
were analysed by SDS–PAGE and visualized by autoradiography. In
lane 1, the equivalent of one-ﬁfth of the 9G8-, SF2/ASF- or
SRp20-expressing rabbit reticulocyte lysate used in each assay was
loaded onto the gel.
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interaction domain of SRp20 with EB2 is located within
the ﬁrst 103 amino acids, which corroborates the ﬁnding
of Verma et al. (27).
Over-expression of SRp20, 9G8 and SF2/ASF induces the
nuclear re-localization of cytoplasmic EB2 mutant
derivatives
Although SRp20 has been previously described as a
shuttling protein, it is mostly detected in the nucleus.
EB2—also a shuttling protein—is similarly predominantly
found at steady state in the nucleus and we have previ-
ously characterized two nuclear localization signals of the
protein in its N-terminal half: an EB2 protein with its ﬁrst
184 amino acids deleted was mostly cytoplasmic.
Furthermore, by mutating two sequences—KRRR
(NLS1: amino acids 126–130) and KRR (NLS2: amino
acids 143–145)—to alanines, the resulting protein, F.EB2
M1.2 was found to be partially cytoplasmic (20). We made
use of these EB2 cytoplasmic mutants to ask whether
over-expression of nuclear SRp20 in HeLa cells would
induce a re-localization of cytoplasmic EB2 mutants into
the nucleus. We thus co-expressed HA-tagged SRp20 with
each one of the three EB2 mutant proteins depicted in
Figure 4A. The respective localization of the proteins
was then visualized by immunoﬂuorescence. As shown in
Figure 4B, SRp20 was efﬁciently over-expressed only in a
subset of the transfected cells (compare panels a, d and g
to panels c, f and i respectively). Interestingly, when we
compared the localization of F.EB2 M1.2 between cells
over-expressing or not SRp20, we found that F.EB2
M1.2 became fully nuclear in cells over-expressing
SRp20 (Figure 4B, panel b). In accordance with this,
similar results were obtained when we used the
F.EB2Cter protein. This protein, mostly cytoplasmic in
cells that did not over-express SRp20, was clearly
concentrated in the nuclei of cells over-expressing the SR
protein (Figure 4B, panel e). In order to determine if the
translocation of cytoplasmic EB2 into the nucleus was due
to a direct interaction with SRp20, we used the F.EB2Nter
M1.2 protein, which does not contain the SRp20 inter-
action domain. Again, due to the mutation of the two
NLS sequences, the protein was mostly cytoplasmic.
This cytoplasmic localization was not affected by the
presence or not, of over-expressed SRp20 (Figure 4B,
panel h). Similar results were obtained with both SF2/
ASF and 9G8 (data not shown). Taken together, these
experiments indicate that EB2 interacts with the three
SR proteins within live cells.
Down-regulation of SRp20 expression by siRNA results in
a strong inhibition of the EB2-dependent cytoplasmic
Renilla luciferase mRNA accumulation
Since we previously reported that EB2 signiﬁcantly
increases the amount of cytoplasmic Renilla luciferase
mRNA expressed from an intronless construct (25), we
asked whether the SR proteins SRp20, 9G8 or SF2/ASF
could play a role in the EB2-dependent cytoplasmic accu-
mulation of this speciﬁc mRNA. The Renilla luciferase
reporter construct pcDNAGlobinRen (Figure 5A) was
thus transfected into HeLa cells, together or not, with
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Figure 4. SRp20 over-expression induces retention of an NLS-deﬁcient
EB2 protein in the nuclei of HeLa cells. (A) Schematic representation of
EB2 and EB2 mutants. (B) HeLa cells were co-transfected with expres-
sion vectors for HA-SRp20 and either FlagEB2 M1.2, FlagEB2Cter or
FlagEB2Nter M1.2. Proteins were visualized by indirect immunoﬂuor-
escence using an anti-HA mAb (for detection of HA-SRp20) (panels a,
d and g) and an anti-Flag polyclonal antibody (for detection of
FlagEB2 protein and mutants as indicated) (panels b, e and h). An
Alexa Fluor 488 goat anti-rabbit antibody and a Fluorolink
Cy3-labelled goat anti-mouse IgG (H+L) antibody were used as sec-
ondary antibodies respectively. Cell nuclei were stained with Hoechst
33258 (Sigma) (panels c, f and i). Red arrows indicate cells in which
SRp20 is over-expressed together with FlagEB2 (or mutant FlagEB2)
whereas white arrows indicate cells in which FlagEB2 (or mutant
proteins) is expressed but SRp20 is not over-expressed.
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Figure 3. Mapping of the interaction domains of EB2 in SRp20.
(A) Schematic representation of SRp20 and deletion mutants.
(B) 35S-labelled EB2 was incubated with puriﬁed GST, GST–SRp20,
GST–SRp20 RRM or GST–SRp20 RS bound to glutathione sepharose
beads. The bound proteins were analysed by SDS–PAGE and
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loaded onto the gel.
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an expression plasmid for EB2 48 h after transfection of
the cells with an siRNA speciﬁc for SRp20, 9G8, SF2/ASF
or a control siRNA. Both the expression level of EB2 and
the efﬁciency of SRp20, 9G8 or ASF/SF2 down-
regulation by the speciﬁc siRNAs were veriﬁed by
western blot analysis as shown in Figure 5B, C and D
respectively). The amount of cytoplasmic luciferase
mRNA was then quantiﬁed by RT–qPCR, normalized
to the amount of GAPDH mRNA and plotted on the
graphs presented in Figure 5E, F and G as relative
mRNA amounts. As we published previously (25), we
found that in cells transfected with a control siRNA, the
presence of EB2 led to a strong increase (16 - to 27-fold) in
the amount of Renilla luciferase mRNA (compare lane 2
to lane 1 in panels E, F and G). When we inhibited en-
dogenous SRp20 expression with a speciﬁc siRNA, EB2
did not induce any increase in the amount of Renilla
luciferase mRNA (compare lane 4 to lane 3 in panel E).
However, it should be noted that depletion of SRp20, in
the absence of EB2, induced a reproducible increase (on
average 5-fold) in the amount of cytoplasmic Renilla
luciferase mRNA (compare lane 3 to lane 1 in panel E).
The results of concomitant quantiﬁcation of Renilla
luciferase nuclear mRNAs (Supplementary Figure S1)
were very similar to those obtained with the cytoplasmic
mRNAs: EB2 induced an increase in the amount of
nuclear luciferase RNA (10-fold). So did SRp20 depletion
by itself (9-fold) and, in this case of SRp20 depletion, EB2
did not increase the amount of nuclear luciferase RNA.
In fact, EB2 rather induced a diminution of nuclear
luciferase RNA in the absence of SRp20. This effect of
SRp20 depletion on both the amount of nuclear and cyto-
plasmic Renilla luciferase RNA, suggests that SRp20
targets this speciﬁc mRNA and either induces its destabil-
ization or stimulates cryptic splicing, which eliminates part
of the luciferase mRNA sequence, including that ampliﬁed
in our RT–PCR reaction.
Inhibition of either 9G8 or SF2/ASF expression
(Figure 5C and D respectively) also affected EB2-
mediated cytoplasmic accumulation of Renilla luciferase
mRNA, although to a much lower extent. Moreover, in
the absence of EB2, depletion of either 9G8 or SF2/ASF
did not have any noticeable impact on the level of the
Renilla luciferase mRNA (Figure 5F and G). The results
of concomitant quantiﬁcation of the nuclear Renilla
luciferase RNAs fully mimicked the results of the quanti-
ﬁcation obtained with the cytoplasmic mRNAs (data not
shown).
Taken together, these results strongly suggest that SR
proteins—and in the case of this speciﬁc mRNA, in par-
ticular SRp20—are required for efﬁcient EB2-dependent
cytoplasmic accumulation of its target mRNAs.
EB2 induces efﬁcient cytoplasmic accumulation of human
b-globin cDNA transcript in a SRp20-dependent manner
In the Renilla luciferase mRNA model, SRp20 appears to
be the main SR protein necessary for EB2-dependent
Figure 5. SRp20 is required for the EB2-dependent cytoplasmic accumulation of Renilla luciferase mRNA. (A) Schematic representation of the
Renilla luciferase intronless-coding vector (pcDNAGlobinRen) showing positions of the CMV promoter and BGH polyadenylation signal. Small
arrows indicate the position of the primers used for the PCR. (B-D) Immunoblots of HeLa cells co-transfected with pcDNAGlobinRen together with
pCI-Flag EB2 as indicated in the ﬁgure. Cells were previously transfected with either a control siRNA (lanes 1 and 2 of each panel) or an siRNA
speciﬁc for SRp20 (panel B, lanes 3 and 4), 9G8 (panel C, lanes 3 and 4) or SF2/ASF (panel D, lanes 3 and 4). The blots were either probed with an
M2-Flag mAb to detect Flag-EB2, an anti-SRp20 mAb, an anti-9G8, an anti-SF2/ASF, or an anti-a-Tubulin as a control of total protein amounts.
(E–G) Quantiﬁcation of cytoplasmic luciferase encoding mRNAs by RT–qPCR using GAPDH as an internal control. mRNAs were extracted from
cells transfected as described in B, C and D respectively. Experiments were made three times and the error bars represent standard deviations.
Nucleic Acids Research, 2012, Vol. 40, No. 14 6841
cytoplasmic accumulation of the mRNA. SRp20 could
be necessary, either for the efﬁcient recruitment/stabiliza-
tion of EB2 to the RNA or on the contrary, SRp20
could be recruited/stabilized onto the RNA by EB2 and
participate actively in the stabilization and export of the
mRNP. Interestingly, Huang and Steitz previously
demonstrated that SRp20 (and 9G8) interacts speciﬁcally
with a 22-nt RNA element from the mouse histone H2a
gene (Figure 6A) (4). Insertion of this 22-nt motif,
upstream of the human b-globin cDNA sequence in
reporter construct b1()2() (Figure 6B) inhibits cryptic
splicing between the b-globin-coding sequence and vector
sequences, improves polyadenylation efﬁciency and
enhances nuclear export. These effects increased with the
number of tandemly repeated copies of the 22-nt element
in a synergistic manner (4). We thus took advantage of
these reporter constructs to study the effect of EB2 in
relation to the presence of well-identiﬁed SRp20/9G8-
binding sites. The constructs depicted in Figure 6B were
thus used in transient transfections, either alone or
together with an expression plasmid for EB2.
Cytoplasmic RNA was then isolated and analysed by
RT–PCR. As expected from the previous results of
Huang and Steitz (4), we observed that the amount of
cytoplasmic b-globin mRNA increased with the
multimerization of the 22-nt motif (Figure 6C, lanes 1,
3, 5 and 7). Interestingly, although EB2 increased the
amount of cytoplasmic b-globin mRNA expressed from
the four b-globin constructs (Figure 6C, lane 2), we
observed that this effect was inversely proportional to
the number of 22-nt motifs present in the reporter con-
structs (Figure 6C, lanes 2, 4, 6 and 8 and Figure 6D).
We then asked whether the effect of EB2 on the
b1()2() RNA was dependent on SRp20 by reiterat-
ing the above experiments in the presence of an
anti-SRp20 siRNA or a control siRNA. The data pre-
sented in Figure 7, show that the EB2-induced increase
in the cytoplasmic accumulation of the b-globin mRNAs
expressed from the b1()2() construct, is strongly de-
pendent on the presence of SRp20. Similarly to what we
observed with the Renilla luciferase mRNA, we noted a
reproducible increase in the amount of cytoplasmic
b-globin mRNA when the cells were depleted of SRp20.
This was not due to an indirect effect on the level of tran-
scription initiated at the b-globin promoter since we did
not observe any difference in the amount of transcripts
generated from the 4-bG construct that contains the
22-nt ‘stabilizing’ motif (data not shown). We also tested
the impact of depleting the cells of either 9G8 or SF2/ASF
by siRNA. Similarly to what was observed with the
luciferase mRNA, the data, presented in Supplementary
Figure S2, show a reproducible diminution of the
EB2-dependent cytoplasmic accumulation of the
b-globin mRNA upon depletion of 9G8 or SF2/ASF.
However, the impact of these depletions on EB2’s
capacity to induce accumulation of these mRNAs in the
cytoplasm is not as drastic as that of SRp20.
Taken together, these data suggest that the effect of
EB2 on the cytoplasmic accumulation of the b-globin
mRNA is highly dependent on the presence of SRp20
but that rather than being recruited onto the mRNA by
D
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Figure 6. Effect of EB2 on the cytoplasmic accumulation of a human
b-globin transcript that carries SRp20-binding sites. (A) Schematic rep-
resentation of the mouse histone H2a 22-nt element. The black rect-
angle represents the 101-nt sequence from the mouse histone H2a
found to facilitate cytoplasmic accumulation of intronless gene tran-
scripts (47). The 22-nt element is shown with the 9G8 and SRp20-
binding sites underlined. (B) Reporter constructs used for measuring
the effect of EB2 in transient transfection experiments. The large open
rectangle represent the human b-globin cDNA sequence, the black
triangle the b-globin polyadenylation signal. An example of cryptic
splicing from the human b-globin-coding region to the vector
sequence is indicated. The grey boxes represent copies of the 22-nt
element inserted at the beginning of the b-globin open reading frame.
The two half arrows indicate the oligonucleotides used for RT–PCR
ampliﬁcations. (C) Autoradiogram of an example of RT–PCR ampliﬁ-
cation of human b-globin RNAs expressed in transfected cells. The
human b-globin plasmids depicted in C were transfected individually
into HeLa cells either alone or together with an expression plasmid for
EB2 as indicated. Forty-eight hours later, cytoplasmic RNAs were
prepared and subjected to RT–PCR using the primer pair indicated
in B (panel a) or a primer pair speciﬁc for b-actin mRNA as internal
control (panel b). (D) Quantiﬁcation of the results of three experiments.
Each band from an experiment similar to that presented in C was
quantiﬁed by using a PhosphorImager. The data are expressed as a
ratio between the amount of cytoplasmic b-globin RNA measured in
the presence of EB2 and the amount of cytoplasmic b-globin RNA
measured in the absence of EB2. The error bars represent standard
deviation.
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speciﬁcally bound-SRp20, EB2 might mimic the effect of
the 22-nt element by recruiting/stabilizing SRp20 onto the
b-globin mRNA.
EB2 increases SRp20 recruitment onto human
b-globin RNA
In order to test our above hypothesis that EB2 increases
SRp20’s binding to b-globin RNA, we performed
RNA-immunoprecipitation experiments. For this, HeLa
cells, transiently transfected with the b1()2() reporter
construct either alone or together with increasing amounts
of an expression vector for EB2, were UV-irradiated to
crosslink proteins to the RNA. SRp20-containing
complexes were then immunoprecipitated with a speciﬁc
anti-SRp20 antibody and RNA prepared from these
immunoprecipitated fractions was analysed by RT–PCR.
As can be seen in Figure 8A, the amount of b1()2()
RNA co-immunoprecipitated with SRp20 increased pro-
portionally with the amount of EB2 expressed in the cells.
We also performed RNA-immunoprecipitation experi-
ments using an anti-Flag antibody to immunoprecipitate
Flag tagged-EB2 in the presence or absence of SRp20.
Figure 8B shows that the amount of b-globin RNA
associated with EB2 remains unchanged when cells are
depleted of SRp20. Taken together, these results indicate
that EB2 bound to b-globin mRNA either recruits SRp20
onto the RNA or stabilizes SRp20’s association with this
mRNA.
EB2 counteracts the deleterious effect of SRp20 on
cytoplasmic accumulation of EBV late viral mRNAs
Since SRp20 has such a drastic effect on two model
mRNAs that depend on EB2 for their efﬁcient accumula-
tion in the cytoplasm, we tested whether depletion of
SRp20 also affected the EB2-dependent cytoplasmic accu-
mulation of speciﬁc viral mRNAs. We have previously
shown that the late BDLF1 and BFRF3 mRNAs are
very poorly expressed following induction of the product-
ive cycle of a recombinant EBV lacking the EB2-coding
gene (18). We thus cloned these two genes under the
control of the CMV promoter into a plasmid lacking
intronic sequences (plasmids pCI-FlagBDLF1-i and
pCI-FlagBFRF3-i respectively) (Figure 9A). These two
constructs were transfected into HeLa cells together (or
not) with an expression plasmid for EB2. Cells were pre-
viously transfected with either a SRp20-speciﬁc siRNA or
a control siRNA. Cytoplasmic RNAs were puriﬁed and
analysed by semi-quantitative RT–PCR (Figure 9B). As
expected, the level of both BFRF3 and BDLF1 mRNAs
were drastically increased in the presence of EB2 (compare
lanes 2 to lanes 1 of each panel). Interestingly, SRp20
depletion also drastically enhanced the level of both
BFRF3 and BDLF1 (compare lanes 3 to lanes 1 of each
panel) and the presence of EB2 had only a minimal (or no)
additive effect in the absence of SRp20. Nuclear RNAs
were also quantiﬁed in these experiments and the results
always mimicked what was seen in the cytoplasm (data
not shown), indicating that the low level of cytoplasmic
mRNA detected in the presence of SRp20 but in the
absence of EB2 was not due to an accumulation of these
mRNAs in the nucleus. These data strongly suggest that
the main effect of EB2 is to counteract a deleterious effect
of SRp20 on intronless viral mRNAs.
In order to investigate the role of SRp20 during the
replicative cycle of EBV, we used the HEK293EBV cell
line. HEK293EBV cells carry an EBV recombinant that
constitutively expresses the Green Fluorescent Protein
(GFP). The replicative cycle of the virus can be activated
in these cells by ectopic expression of the immediate early
EBV transactivator EB1 (also called Zta or zebra).
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Figure 7. SRp20 is required for the EB2-dependent cytoplasmic accu-
mulation of human b-globin cDNA transcripts. (A) Immunoblots of
HeLa cells co-transfected with the b1()2() reporter construct
together with an EB2 expression plasmid as indicated in the ﬁgure.
Cells were previously transfected with either a control siRNA (lanes
1 and 2) or a siRNA speciﬁc for SRp20 (lanes 3 and 4). The blots were
probed with either a M2-Flag mAb to detect tagged Flag-EB2, an
anti-SRp20 mAb or an anti-a-Tubulin as a control of total protein
amounts. (B) Autoradiogram of an example of RT–PCR ampliﬁcations
of human b-globin RNAs expressed in cells tranfected as indicated in
A, using the primer pair speciﬁc for human b-globin RNA (top panel)
or a primer pair speciﬁc for actin RNA as internal control (bottom
panel). (C) Quantiﬁcation of the results of three experiments using a
PhosphorImager. The error bars represent standard deviation.
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The amount of virus produced is then quantiﬁed following
infection of Raji cells, by counting the number of
GFP-expressing cells (43). We thus transfected
HEK293EBV cells with a SRp20-speciﬁc siRNA or a
control siRNA prior to transfection with the EB1 expres-
sion plasmid. As shown Figure 9C, virus production from
cells in which SRp20 is down-regulated was reproducibly
higher. This effect of SRp20 depletion on virus production
was not unexpected since we have shown above, in the
case of the two late viral mRNA, BDLF1 and BFRF3,
that SRp20 depletion itself induced the cytoplasmic accu-
mulation of these two mRNAs, even in the absence of
EB2. In accordance with these results, over-expression of
SRp20 in HEK293EBV cells led to a diminution of virus
production (data not shown). We then asked whether
SRp20 depletion by itself could induce virus production
in the absence of EB2. For this we repeated the above
experiments with HEK293EBV-BMLF1KO cells that carry
an EBV recombinant with the EB2-coding gene deleted
(16). The results shown Figure 9D indicate that in the
absence of EB2, SRp20 depletion was clearly not sufﬁcient
to increase virus production. It is interesting to note that
when we trans-complemented the HEK293EBV-BMLF1KO
cells depleted of SRp20 with an EB2 expression plasmid,
we observed an increase in virus production very similar to
that observed in the HEK293EBV cells treated with the
SRp20 siRNA.
Taken together, these results suggest that one of the
mechanisms by which EB2 stimulates the cytoplasmic
accumulation of viral mRNAs is by counteracting the
negative effect of SRp20 on these same mRNAs.
DISCUSSION
The EBV early protein, EB2, has been found to affect
multiple cellular pathways involved in mRNA processing.
It was thus interesting to better understand how EB2
interacts with the cellular network of proteins involved
in mRNA processing. We approached this question
by setting up a wide-scale yeast two-hybrid screen.
Although probably not completely exhaustive, this
screen allowed us to identify 42 putative cellular
partners for EB2. Among these, only Sp100 (46) and
RBM15b/OTT3 (21) had been previously described as
being direct interactors of the viral protein. Sp100 is a
component of PML bodies, which are disrupted upon
EBV productive cycle reactivation (48). RBM15b/OTT3
directly interacts with NXF1 and acts at the
post-transcriptional level to activate reporter gene expres-
sion (23). hnRNPC was previously found to be present in
a complex with EB2, although no direct interaction was
demonstrated (49). That we have now identiﬁed this
protein in our Y2H screen argues for a direct interaction
between hnRNPC and EB2. Interestingly, in our list of
novel interactors, we found several proteins known for
their implication in splicing (PUF60, SF3A2, SRSF1,
SRSF3, SRSF7 and ZRSR2) including several members
of the SR family of proteins. Previously, another member
of the SR family, SFRS10, was also found to interact with
EB2 in a yeast 2YH screen (46). Furthermore, SRp20
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Figure 8. b-globin RNA-immunoprecipitation by anti-EB2 and anti-
SRp20 antibodies. (A) HeLa cells were transfected with the
b1()2() reporter construct together with increasing amounts (0, 0.5
or 1mg) of Flag-tagged EB2 expression plasmid. After UV treatment
of the cells, SRp20 containing complexes were immunoprecipitated
using the anti-SRp20 mAb 7B4. RNA was then puriﬁed and the
amount of speciﬁc b1()2() transcripts (panel a) or actin control
mRNAs (panel b) co-immunoprecipitated was evaluated by semi-
quantitative RT–PCR. The respective amounts of EB2 (panel c) and
SRp20 (panel d) present in the samples used in the RNA-
immunoprecipitations were evaluated by western blot analysis. (B)
HeLa cells were transfected with the b1()2() reporter construct
together with a Flag-tagged EB2 expression plasmid after transfection
of the cells with an anti-SRp20 siRNA or a control siRNA as
indicated. After UV treatment of the cells, EB2-containing complexes
were immunoprecipitated using an anti-Flag M2 antibody. RNA
was then puriﬁed and the amount of speciﬁc b1()2() transcripts
(panel a) or actin control mRNA (panel b) co-immunoprecipitated
was evaluated by semi-quantitative RT–PCR. The respective amounts
of EB2 (panel c) and SRp20 (panel d) present in the samples used
in the RNA-immunoprecipitations were evaluated by western blot
analysis.
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(SRSF3) was recently afﬁnity puriﬁed in a complex with
EB2 (27). The characterization of interactions between
EB2 and several proteins involved in splicing was quite
striking. Interestingly, these same three SR proteins were
recently found to interact with IE4, the EB2 orthologue in
varicella zoster (13) but the functional impact of these
interactions was not studied. SRp20 also interacts with
ICP27, the EBV orthologue in HSV1 (50). Both SRp20
and 9G8 co-localizes with ICP27 in HSV-infected cells and
their down-regulation by use of speciﬁc siRNAs, reduces
viral yields (51). However, the mechanisms by which
SRp20 and 9G8 down-regulation exert this effect were
not deciphered. We thus decided to study in more detail
the interaction between EB2 and the three SR proteins
identiﬁed in our screen.
We ﬁrst conﬁrmed the interaction between EB2 and the
three SR proteins both by co-immunoprecipitation in
mammalian cells and by GST–pull down. All experiments
were realized in the presence of RNase showing that the
interactions are RNA-independent. We also demonstrated
the interaction in live cells, since over-expression of each
of the three SR proteins is able to induce the nuclear
re-localization of a cytoplasmic form of EB2 generated
by mutating its two NLS (20). Although SF2/ASF,
SRp20 and 9G8 are known to shuttle continuously
between the nucleus and the cytoplasm (52) their
apparent localization in cells is nuclear. EB2 is also a
shuttling protein with a predominant nuclear localization:
we previously showed that the cellular nuclear mRNA
export protein NXF1 participates in the nuclear export
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Figure 9. Impact of SRp20 depletion on the cytoplasmic accumulation of late viral mRNAs and on the production of virions. (A) Schematic
representation of the pCI-BDLF1-i and pCI-BFRF3-i expression plasmids. (B) HeLa cells were co-transfected with pCI-BDLF1-i or
pCI-BFRF3-i together or not with an EB2 expression plasmid. Cells were previously transfected with an anti-SRp20 siRNA or a control siRNA
as indicated. Twenty-four hours later, cytoplasmic RNAs were prepared and subjected to RT–PCR using primer pairs speciﬁc for BDLF1 and
BFRF3 respectively (panels a) or a primer pair speciﬁc for b-actin mRNA as internal control (panels b). (C) The EBV replicative cycle was induced
in HEK293EBV cells previously treated with a SRp20 siRNA or a control siRNA, by transfection of an EB1 (BZLF1) expression plasmid. Cells
supernatant were recuperated 72 h later and used to infect Raji cells. The number of GFP-expressing Raji cells was then evaluated 72 h later by
FACS analysis. The efﬁciency of EB2 expression and SRp20 depletion was evaluated by western analysis and shown in the lower panels. (D) The
EBV replicative cycle was induced in HEK293EBV-BMLF1KO cells previously treated with a SRp20 siRNA or a control siRNA, by transfection of an
EB1 (BZLF1) expression plasmid together or not with an expression plasmid for EB2. Cells supernatant were recuperated 48 h later and used to
infect Raji cells. The number of GFP-expressing Raji cells was then evaluated 72 h later by FACS analysis. The efﬁciency of EB2 expression and
SRp20 depletion was evaluated by western blot analysis and shown in the lower panels.
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of EB2 by binding to an NES sequence present in its
N-terminal (24). Moreover, we have mapped two
nuclear localization sequences (NLS) rich in KR residues
that are responsible for nuclear import (20). However,
mutation of the two NLS sequences of EB2 was not
sufﬁcient to completely inhibit translocation of EB2
from the cytoplasm to the nucleus. Our new data suggests
that the interaction of EB2 with the SR proteins could
result in the active translocation of EB2 from the cyto-
plasm to the nucleus or in its retention in the nucleus.
One of the main functions of EB2 in the productive
cycle of EBV is to stimulate the cytoplasmic accumulation
of most of the early and late viral mRNAs whose particu-
larity is to be expressed from intronless genes (16,18,53).
We thus tested the importance of the interaction between
EB2 and the SR proteins for the cytoplasmic accumula-
tion of mRNA generated from intronless genes. For this,
we used two different reporter models: the ﬁrst is based on
an intronless reporter construct coding for the Renilla
luciferase. We previously found that EB2 stimulates
both cytoplasmic accumulation of the mRNA transcribed
from this construct and ensures its efﬁcient translation
(25). The second model is a reporter construct carrying
the human b-globin cDNA (4). Interestingly, by using
siRNA we found that SRp20 depletion induced an
increase in the cytoplasmic accumulation of both
mRNAs and that in this case of SRp20 depletion, EB2
did not increase further the amount of mRNA in the cyto-
plasm. Since depletion of either 9G8 or SF2/ASF had only
limited effect in the same kind of experiments, we decided
to focus on SRp20. Interestingly, we found that SRp20
affected in a very similar manner two EBV late mRNAs
originated from the BFRF3 and BDLF1 genes respect-
ively. In all cases, depletion of SRp20 by itself induced a
strong accumulation of the mRNA in the cytoplasm and
EB2 had no or little additive effect on the amount of cyto-
plasmic mRNA. It is also important to note that when we
quantiﬁed the amount of nuclear RNA for these speciﬁc
transcripts, we observed that their abundance is very low
(at least 1/20th of the cytoplasmic RNA) and varies in the
same proportions as that of their corresponding cytoplas-
mic RNA. These data suggest that SRp20 exerts a
negative effect on the amount of each of the four tran-
scripts we have analysed in this study. This effect is likely
to be nuclear since SRp20 depletion affects the amount of
nuclear RNA in the same way as the amount of cytoplas-
mic RNA. In this context, it appears that one of the main
functions of EB2 is to counteract this negative effect of
SRp20.
How SRp20 so drastically induces a diminution of these
four different mRNA species is still under study.
However, several mechanisms can be invoked, such as
induction of usage of cryptic splice sites, leading to the
elimination of part of the original RNA, which renders
the RNA undetectable by our PCR ampliﬁcation, or
destabilization of the mRNA. Our preliminary data
suggest that both mechanisms could be involved in this
effect of SRp20 (unpublished data).
The way EB2 counteracts these negative effects of
SRp20 is still speculative but the data presented in this
study by using a reporter construct carrying the human
b-globin cDNA as a model, support the idea that by inter-
acting with SRp20-speciﬁc mRNA targets, EB2 stabilizes
SRp20 onto the mRNA. In effect, by using RNA-
immunoprecipitations, we found that EB2 induced an
increase association of SRp20 with the b-globin transcript.
Interestingly, it was previously shown (4,54), that the
RNA synthesized from this construct is inefﬁciently
polyadenylated and poorly exported to the cytoplasm.
Furthermore, cryptic splicing between the b-globin-
coding sequence and vector sequences also contributed
to lower the global amount of b-globin mRNA. The intro-
duction in this construct of several copies of the mouse
histone H2a 22-nt sequence that is speciﬁcally bound by
the SR proteins, SRp20 or 9G8, was shown to promote
inhibition of cryptic splicing and to enhance
polyadenylation and nuclear export (4). By recruiting or
stabilizing a direct interaction of SRp20 onto the b-globin
mRNA, EB2 would appear to mimic the effect of the
multimerized 22-nt element. SR protein-binding sites are
largely degenerated and difﬁcult to predict. Interestingly,
wide-scale analyses have recently shown that SRp20 asso-
ciates in vivo with a great number of mRNAs, including
intronless mRNAs (55,56). Thus, SRp20 might interact at
low afﬁnity with several non-repertoriated sites on the
b-globin mRNA. EB2 bound to the b-globin mRNA
would then stabilize SRp20’s association to this RNA re-
sulting in a better polyadenylation of the transcript and
inhibition of cryptic splicing. Furthermore, both SRp20
and EB2 can directly interact with NXF1 and thus lead
to efﬁcient nuclear export of their associated mRNPs
(24,57).
In this study, we have described a mechanism by which
EB2 recruits/stabilizes SR proteins onto mRNA generated
from intronless genes. Since SR proteins are known for
their role in both constitutive and alternative splicing, this
suggests that EB2 might interfere with cellular mRNA
splicing. Indeed, we have previously shown in different
models that EB2 favours cytoplasmic accumulation of
un-spliced mRNA with respect to spliced mRNAs
generated from the same gene, especially when the
spliced mRNAs are generated via cryptic splice sites, as
is the case for the b-thalassemia gene (58). Moreover,
Verma et al. (26) have recently shown that EB2 modulates
the splicing of various cellular genes, including STAT1. In
the case of STAT1, EB2 appears to change the ratio
between two functionally distinct isoforms of STAT1
generated by alternative splicing (59) and SRp20 has
been found to be involved in this modulation of STAT1
alternative splicing by EB2 (27). Whether this effect on
cellular genes is important for EBV’s replication remains
to be demonstrated.
Given the drastic effect of SRp20 depletion on several
EB2-target mRNAs, including two late EBV mRNAs, we
were of course interested in evaluating the effect of SRp20
depletion on the EBV replicative cycle itself. However,
since one of the functions of EB2 is to counteract the
negative effect of SRp20 on the accumulation of speciﬁc
mRNA targets, we could expect that SRp20 depletion, in
the presence of EB2, might not have any effect at all,
which is exactly what we observed. In fact, we even
observed a slight but reproducible increase in virus
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production when SRp20 was down-regulated. In accord-
ance, over-expression of SRp20 slightly diminished virus
production (unpublished observations). It is interesting to
note that SRp20 depletion has a very different impact on
the EBV and HSV replicative cycle respectively since in
HSV-infected cells SRp20 down-regulation was found to
reduce viral yields (51). These results conﬁrm once again
that although these two orthologues are both necessary
for the efﬁcient cytoplasmic accumulation of their respect-
ive viral mRNAs, their mechanisms of action are clearly
different which explains that ICP27 cannot trans-
complement an EB2 compromised EBV recombinant (16).
By using cells infected by a virus recombinant with the
EB2-coding region deleted, we asked whether SRp20 de-
pletion could by itself allow the production of viruses in
the absence of EB2, which was not the case. Again, this
result was not unexpected since EB2 has also been
reported to stimulate translation of its target mRNAs
(25), which could be a limited step for the progression of
the viral replicative cycle. Furthermore, although we have
not as yet identiﬁed any, some of the early or late viral
mRNAs might be more sensitive to a similar effect of
other SR proteins. Interestingly, it has been recently
shown that each SR protein accumulates in vivo on a
distinct set of mRNAs (55,56). It is thus likely that SF2/
ASF or 9G8 could fulﬁl the same function as SRp20 for
EB2-mediated cytoplasmic accumulation of mRNA
species other than those used in this study, depending on
their pattern of association with different RNAs.
In conclusion we report here a novel mechanism by
which the EBV protein EB2 favours the efﬁcient accumu-
lation of viral mRNAs generated from intronless genes by
antagonizing the negative effect of SRp20 on these
mRNAs.
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